在全球肥胖趋势的驱动下,每月可注射的肥胖药物到2033年可能成为125.3B美元的市场。 Monthly injectable obesity drugs could become a $125.3B market by 2033, driven by global obesity trends.

全球数据(GlobalData)的一份新报告指出,在全球肥胖率上升的驱动下,每月注射的肥胖症药物可能成为治疗肥胖症的下一个大事。 A new report by GlobalData indicates that monthly injectable obesity drugs could become the next big thing in treating obesity, driven by rising global obesity rates. Amgen和Metsera等公司正在研制这些超长效药物,预计对病人更有效,负担更轻。 Companies like Amgen and Metsera are developing these ultra-long-acting medications, which are expected to be more effective and less burdensome for patients. GlobalData预测GLP-1R实验家到2033年将达到1 253亿美元的销售额,其中90%来自肥胖症药物。 GlobalData predicts GLP-1R agonists will reach $125.3 billion in sales by 2033, with 90% from obesity drugs.